Organon Tempers Expectations Ahead Of Adalimumab Second Wave
Firm Prepares To Launch Both High- And Low-Concentration US Humira Biosimilars
Ahead of joining a second wave of Humira biosimilars hitting the US market in just a couple of months, Organon has projected a “modest ramp” in initial sales for its Hadlima version in 2023.
